SpectraCure AB

SPEC

SE0007158118

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Stockholm Other stock markets 08:59:38 10/05/2024 pm IST			5-day change	1st Jan Change
2.99 ^SEK	0.00%		-6.56%	-22.54%

23/02	Spectracure AB Continues in the Process of Initiating A Clinical Study, for Primary Localised Prostate Cancer	CI
22/02	SpectraCure AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about SpectraCure AB

Spectracure AB Continues in the Process of Initiating A Clinical Study, for Primary Localised Prostate Cancer	23/02	CI
SpectraCure AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	22/02	CI
SpectraCure AB Conducts a Clinical Study for Patients with Recurrence of Prostate Cancer After Radiotherapy	19/12	CI
SpectraCure AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	16/11	CI
SpectraCure AB Decides to Seek Approval for Clinical Study of Primary Prostate Cancer	16/11	CI
SpectraCure AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	17/23/17	CI
SpectraCure Receives an Additional EU Grant	27/23/27	CI
SpectraCure AB Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16	CI
SpectraCure AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	22/23/22	CI
SpectraCures Signs Letter of Intent with Cheplapharm	07/22/07	CI
SpectraCure AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	17/22/17	CI
SpectraCure AB(OM:SPEC) dropped from S&P Global BMI Index	19/22/19	CI
SpectraCure Receives Patent Approval From EPO For Treatment Systems	30/22/30	MT
European Patent Office Approves Spectracure AB's Patent Application Relating to the Technical Solution in the New Generation of Treatment Systems	30/22/30	CI
SpectraCure AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	26/22/26	CI
SpectraCure Receives EU Grant For Industrialization Of Prostate Cancer Drug	07/22/07	MT
SpectraCure AB Announces Board Appointments	16/22/16	CI
SpectraCure AB Reports Earnings Results for the First Quarter Ended March 31, 2022	12/22/12	CI
SpectraCure AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	17/22/17	CI
SpectraCure AB Reports Earnings Results for the Full Year Ended December 31, 2021	17/22/17	CI
SpectraCure AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	16/21/16	CI
SpectraCure AB Reports Earnings Results for the Second Quarter Ended June 30, 2021	25/21/25	CI
Spectracure AB Publ Reports Earnings Results for the First Quarter Ended March 31, 2021	18/21/18	CI
SpectraCure AB Announces Decline Re-Election of Masoud Khayyami as Board Member	15/21/15	CI
Spectracure AB Provides Update Regarding Clinical Studies for the Treatment of Patients with Recurrent Prostate Cancer	05/21/05	CI

SpectraCure AB (publ) is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in cancer treatment technology. The Company develops photodynamic therapeutics based on photosensitive materials activated by laser. The Company's method is called interstitial photodynamic therapy (PDT). Interstitial PDT can be used for solid tumors in internal organs, such as cancer in the prostate, pancreas, and the head and neck area, among others. In addition, the Company offers software platform IDOSE for interstitial PDT treatment of solid cancer tumors in internal organs. With SpectraCureâs interstitial PDT method, the patient is given a photoactivated drug - photosensitizer in combination with laser light guided by a dose control system.

Sector

Advanced Medical Equipment & Technology

Calendar

16/05/2024 - Annual General Meeting

More about the company